Article Text
Statistics from Altmetric.com
- Pulmonary embolism
- aspergillus lung disease
- imaging/CT MRI
- sarcoidosis
- occupational lung disease
- interstitial fibrosis
- COPD epidemiology
- emphysema
- bronchiectasis
- bronchoscopy
- cystic fibrosis
- lung cancer
- COPD mechanisms
- asthma
- asthma mechanisms
- COPD exacerbations
- lung cancer
- cough/mechanisms/pharmacology
We thank Dr Young for his comments on the recent UKLS position statement.1 We are aware of the current studies on chronic obstructive pulmonary disease (COPD) and lung cancer. However, there is no validated lung cancer risk model in the UK which currently incorporates dynamic lung volumes that could be used in the UKLS trial. All the recruited individuals will have spirometry at the time that they are recruited into the UKLS trial, thus data will be available for developing the Liverpool Lung Project risk model.2 ,3 We do not wish to focus on COPD risk groups for the pilot UKLS trial.
Smoking is the over-riding risk factor in lung cancer. Our measurements will provide further information concerning the potential for COPD as a useful factor in selecting populations that may benefit from screening. We do not have population-based spirometry in the UK to screen populations and there is an issue over the diagnostic crossover between COPD and asthma.
The search for molecular biomarkers and susceptibility genes, which may be used in early detection programmes, has proved challenging; although there are a number of promising candidates,4–7 none, to date, has been validated to a level where they can be used in an early lung cancer clinical trial.
Linked Articles
- PostScript
- PostScript